TKA Melatonin and Sleep Quality
- Conditions
- KneeSleep Initiation and Maintenance DisordersReplacementArthroplasty
- Interventions
- Dietary Supplement: Placebo (Vitamin C)Dietary Supplement: Melatonin 5 mg
- Registration Number
- NCT05332717
- Lead Sponsor
- Hospital for Special Surgery, New York
- Brief Summary
This randomized controlled trial (RCT) will compare the effects of melatonin vs. placebo in patients undergoing primary total knee arthroplasty (TKA). This RCT aims to study the effects melatonin has on sleep quality after TKA. Patients will be blinded to their respective groups and will be instructed to take either 5mg melatonin or a placebo pill (Vitamin C) for 6 weeks postoperative. Sleep quality surveys will be administered preoperatively and post-operative week 6, 90-days and 1 year. Poor sleep quality is a common issue faced by patients undergoing TKA. The goal of this study is see if melatonin can improve postoperative sleep quality, and if so, does improved sleep quality correlate to improvements in other postoperative outcomes.
- Detailed Description
This study will compare postoperative sleep quality in two groups of patients undergoing primary total knee arthroplasty (TKA):
* Group 1 will take one melatonin (5 mg) tablet nightly, \~30 minutes before bedtime during the 6 week postoperative period
* Group 2 will take one placebo (5 mg Vitamin C) tablet nightly, \~30 minutes before bedtime during the 6 week postoperative period
The primary outcome will be sleep quality at 6 weeks. Sleep quality will be measured using the Pittsburgh Sleep Quality Index (PSQI). The survey will be administered preoperatively, 6-weeks, 90-days and 1 year postoperatively. Preoperative surveys will be completed in-person, on-site by study participants. All postoperative surveys will be distributed via email.
Secondary outcomes include:
* (KOOS Jr, LEAS, VR-12, VAS) administered preoperatively, at 6-weeks, 90-days and 1-year post-operatively.
* Total opioids prescribed in first 3 months postoperative will be collected using iStop
* Frequency of CMS defined surgicalcomplications in the first 90-days after primary TKA.
* Adverse events of Melatonin during the first 6 weeks (collected via email survey sent to participants once per week, for the first 6 weeks)
* Study medication compliance at 6 weeks (collected via email survey sent to participants once per week, for the first 6 weeks)
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 176
- Patients undergoing primary, unilateral TKA
- Primary diagnosis of osteoarthritis (OA)
- Aged 18+
- Subject is opioid naive (has not taken opioids during the 6 months prior to surgery)
- Subject is not currently taking sleep medication
- English speaking
- Has working email (for survey purposes)
-
Patients with diagnosis other than OA including: Inflammatory arthritis; Post-traumatic OA; Chronic pain; Insomnia*; Depression*; Anxiety*; Any active sleep disorder
-
Planned contralateral knee or subsequent total joint arthroplasty within 90 days
-
Any planned surgery within 90 days
-
Patient taking medication for depression or insomnia or anxiety during the 6 months prior to surgery
-
Patients with renal or hepatic disorders as these can affect melatonin metabolism
- Insomnia, anxiety, and depression will be defined as use of controlled medication for that disorder which will be identified in istop or HSS record of the patient filled in the 6 months prior to surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Group (Control) Placebo (Vitamin C) Patients who will take one (1) placebo (Vitamin C) tablet 30 minutes before bedtime daily for the 6 weeks following surgery. Melatonin Group (Experimental) Melatonin 5 mg Patients who will take one (1) 5mg Melatonin tablet 30 minutes before bedtime daily for the 6 weeks following surgery.
- Primary Outcome Measures
Name Time Method Sleep Quality 1-year Assessed based on self-reported data collected using the Pittsburgh Sleep Quality Index (PSQI). Minimum Score: 0; Maximum Score: 21. Higher scores indicate a worse outcome.
- Secondary Outcome Measures
Name Time Method Overall Health Preoperatively, 6-week, 90-day and 1-year follow-up Assessed based on self-reported data collected using the Veterans Rand 12 (VR-12) Scale. Minimum Score: 0; Maximum Score: 100. Higher scores indicate a better outcome.
Knee Function Preoperatively, 6-week, 90-day and 1-year follow-up Assessed based on self-reported data collected using the abbreviated Knee Injury and Osteoarthritis Outcome Score (KOOS Jr). Minimum Score: 0; Maximum Score: 28. Higher scores indicate a better outcome.
Lower Extremity Activity Preoperatively, 6-week, 90-day and 1-year follow-up Assessed based on self-reported data collected using the Lower Extremity Activity Scale (LEAS). Minimum Score: 1; Maximum Score: 18. Higher scores indicate a better outcome.
Pain Ratings Preoperatively, 6-week, 90-day and 1-year follow-up Assessed based on self-reported data collected using the Visual Analogue Pain Scale. Minimum Score: 0; Maximum Score: 10. Higher scores indicate a worse outcome.
Opioids Prescribed 90-day follow-up This will me quantified in morphine milligram equivalents (MMEs). This information will be obtained for each patient using institutionally queried i-Stop data.
Study Medication Compliance Weekly (Up to 6 weeks) Assessed based on self-reported data collected via study survey.
Quantity of Postoperative Centers for Medicare and Medicaid Services Complications 90-day follow-up Assessed using institutional medical record data.
Quantity of Adverse Melatonin Medical Events Weekly (Up to 6 weeks) Assessed based on self-reported data collected via study survey.
Trial Locations
- Locations (1)
Hospital for Special Surgery
🇺🇸New York, New York, United States